健脾通络汤对脾胃虚寒型Hp阳性慢性萎缩性胃炎患者血清G-17、胃蛋白酶水平及免疫功能的影响

doi:10.3969/j.issn.1001-8131.2023.02.042

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (427 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨健脾通络汤治疗脾胃虚寒型幽门螺杆菌（Hp）阳性慢性萎缩性胃炎（CAG）的临床效果及安全性。方法选取88例Hp阳性CAG患者,按随机数字表法分为对照组（44例）与观察组（44例）。对照组予以三联疗法治疗,观察组加用健脾通络汤治疗,持续用药1个月。比较两组临床疗效、血清胃泌素-17（G-17）、胃蛋白酶水平、免疫功能及安全性。结果观察组总有效率高于对照组,差异有统计学意义（P<0.05）;观察组治疗后G-17[（386.74±38.64）ng/L]、胃蛋白酶原Ⅰ（PGⅠ）[（58.13±5.33）μg/L]高于对照组[（342.89±35.79）ng/L、（54.15±5.25）μg/L],胃蛋白酶原Ⅱ（PGⅡ）[（10.35±1.53）μg/L]低于对照组[（13.68±1.71）μg/L],差异有统计学意义（P<0.05）;观察组治疗后CD₄⁺[（45.85±4.82）%]、CD₄⁺/CD₈⁺[（1.85±0.28）]高于对照组[（41.41±4.56）%、（1.58±0.26）],CD₈⁺[（24.85±2.11）%]低于对照组[（26.23±2.27）%],差异有统计学意义（P<0.05）;两组均无严重不良反应。结论健脾通络汤可提高脾胃虚寒型Hp阳性CAG治疗效果,纠正患者免疫功能异常,加快G-17、PGⅠ、PGⅡ复常,安全可靠。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李长路

关键词 ：慢性萎缩性胃炎, 脾胃虚寒, 健脾通络汤, 胃蛋白酶, 免疫功能, 安全性

Abstract：Objective To explore the clinical effect and safety of Jianpi Tongluo Decoction in the treatment of Helicobacter pylori（HP）- positive chronic atrophic gastritis（CAG）of spleen stomach deficiency and cold type. Methods 88 patients with HP positive CAG treated were randomly divided into control group（44 cases）and observation group（44 cases）.The control group was treated with triple therapy,and the observation group was treated with Jianpi Tongluo Decoction for 1 month.The clinical efficacy,serum gastrin-17（G-17）,pepsin level,immune function and safety were compared between the two groups. Results the total effective rate of the observation group was higher than that of the control group（P<0.05）;G-17 [（386.74 ± 38.64）ng /L] and pepsinogen Ⅰ（PG Ⅰ）[（58.13±5.33）in the observation group after treatment μg/L] was higher than that in the control group [（342.89±35.79）ng/L,（54.15±5.25）μg/L],pepsinogen Ⅱ（PG Ⅱ）[（10.35±1.53）μg/L] was lower than that in the control group [（13.68±1.71）μg/L],with statistical difference（P<0.05）;After treatment,CD4+ [（45.85±4.82）%] and CD4+/CD8+ [（1.85±0.28）] in the observation group were higher than those in the control group [（41.41±4.56）%,（1.58±0.26）],and CD8+ [（24.85±2.11）%] were lower than those in the control group [（26.23±2.27）%]（P<0.05）;There were no serious adverse reactions in both groups. Conclusion Jianpi Tongluo Decoction can improve the therapeutic effect of HP positive CAG of spleen stomach deficiency cold type,correct the abnormal immune function of patients,and accelerate the normalization of G-17,PG Ⅰ and PG Ⅱ.It is safe and reliable.

Key words： chronic atrophic gastritis Deficiency cold of spleen and stomach Jianpi Tongluo Decoction Pepsin immunity Security

收稿日期: 2022-05-07

PACS:

R573.3+2

引用本文:

李长路. 健脾通络汤对脾胃虚寒型Hp阳性慢性萎缩性胃炎患者血清G-17、胃蛋白酶水平及免疫功能的影响[J]. 哈尔滨医药, 2023, 43(2): 114-116.
Li Changlu. Effect of Jianpi Tongluo Decoction on Serum G-17,Pepsin Level and Immune Function in Patients with HP Positive Chronic Atrophic Gastritis of Spleen Stomach Deficiency Cold Type. journal1, 2023, 43(2): 114-116.

链接本文:

http://www.hrbyybjb.org.cn/CN/10.3969/j.issn.1001-8131.2023.02.042 或 http://www.hrbyybjb.org.cn/CN/Y2023/V43/I2/114

[1] 冯庆. 荆花胃康胶丸联合瑞巴派特治疗慢性萎缩性胃炎的临床研究[J].现代药物与临床,2021,36(5):952-956.
[2] 王静,倪建俐,王萍,等.养阴利湿方治疗慢性萎缩性胃炎的疗效及对血清胃蛋白酶原,胃泌素的影响[J].医学综述,2021,27(2):413-417.
[3] 姚鹏,康洪昌,王江,等.荜铃胃痛颗粒联合三联疗法治疗慢性萎缩性胃炎合并幽门螺杆菌感染的临床研究[J].天津中医药,2021,38(9):1138-1143.
[4] 张曼,高炳霞,齐颖,等.依卡倍特钠联合常规四联疗法对幽门螺杆菌阳性慢性萎缩性胃炎的疗效观察[J].现代消化及介入诊疗,2020,25(1):76-79.
[5] 兰青,马尚清,赵兵,等.健脾通络汤治疗慢性萎缩性胃炎伴广泛肠化脾胃虚弱证的疗效观察[J].中华中医药杂志,2019,34(8):3880-3882.
[6] 钱家鸣,历有名,林菊生,等.消化内科学[M].北京:人民卫生出版社,2014:68-79.
[7] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:189-190.
[8] 李德成,张守菊,李霞.胃炎宁颗粒联合维酶素治疗慢性萎缩性胃炎的临床研究[J].现代药物与临床,2019,34(5):1379-1383.
[9] 张紫涵,陈俊,徐丹.苦参碱联合胃复春片治疗慢性萎缩性胃炎疗效及对患者血清胃蛋白酶原亚群的影响[J].陕西中医,2021,42(3):323-325,333.
[10] 马润兴,马玉寿.自拟温胃散寒汤治疗脾胃虚寒型慢性萎缩性胃炎的临床效果[J].中国医药导报,2019,16(25):118-121.
[11] 叶骏,苗丽,郑安斌,等.摩罗丹联合奥美拉唑治疗对慢性胃炎患者疗效及炎症因子、胃蛋白酶原水平的影响[J].海军医学杂志,2020,41(5):548-551.
[12] 王国庆,刘红军,梁素芳.益气活血方联合三联疗法对气虚血瘀型慢性萎缩性胃炎患者炎性反应和血液流变学的影响[J].世界中医药,2019,14(1):182-186.